Protease inhibitors as antivirals

A method to treat a viral infection, which comprises administering to a subject in need of such treatment a compound of Formula (I):

• or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof;
• or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
• wherein:
• Z is selected from —CH2CN, —C(═O)—CH═CH2, and —CH(OH)SO3− (and an associated cation, optionally wherein the cation is Na+);
• L is —C(═O)—NH—;
• R1 is
• R2 is selected from C1-6 alkyl, 3-7 membered cycloalkyl, C1-3 alkyl-(3-7 membered cycloalkyl), and (3-7 membered cycloalkyl)-C1-3 alkyl, each of which is optionally substituted with up to three groups selected from halo, CN, C1-3 alkyl, C1-6 alkoxy, C1-3 haloalkyl, and C1-3 haloalkoxy;
• R3 is H or C1-4 alkyl;
• each R* is independently selected from C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, CN, halo, and —OH;
• m is an integer from 0 to 2;
• and
• n is an integer from 0 to 4 wherein the viral infection is a coronavirus infection.